Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis PatientsGlobeNewsWire • 09/20/19
Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)Zacks Investment Research • 09/10/19
Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical ExecutiveGlobeNewsWire • 08/26/19
Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving DialysisGlobeNewsWire • 08/21/19
FibroGen, Inc. (FGEN) CEO Tom Neff on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/09/19
FibroGen's Roxadustat Shows A Clear Positive Phase III MACE Result, But Future Sales Remain UncertainSeeking Alpha • 05/22/19